• Wednesday, May 16, 2018 @ 6:45 am

ValuationLab published an update of the Basilea Valuation Report “Piece de resistance” see below PDF.

Basilea has continued to expand the global reach of its key products Cresemba and Zevtera through license and distribution agreements in 2017 that cover more than 100 countries with CHF 80 mn in upfront payments and up to USD 1.1 bn potential milestones payments. The company made significant clinical progress with its key pipeline products, including the kick off of US development of Zevtera with the start of the first of the two cross-supportive phase III trials under SPA in severe skin infections in February 2018. Basilea also expanded it oncology pipeline with the promising oral FGFR inhibitor derazantinib for treating solid tumors from ArQule in April 2018.

Key catalysts include:

  • Start of US phase III trial Zevtera in bacteremia (mid 2018)
  • Interim analysis derazantinib in iCCA (mid 2019)
  • Phase I results oral BAL101553 (2019)

You may also be interested in